Physician profile
John Gannon
NPI 1861634289
$1,607.19
in general payments reported to CMS, 2019-2025
22 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $65.98 · 2021: $64.11 · 2022: $184 · 2023: $149 · 2024: $290 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $603.90 | 2022-2025 | Lumenis Pulse 120h, Spaceoar Vue System - 10ml |
| Abbvie INC. | $183.48 | 2019-2025 | |
| Astellas Pharma US INC | $110.36 | 2019-2024 | Myrbetriq |
| Janssen Biotech, INC. | $74.93 | 2019-2024 | Erleada, Akeega |
| Endo USA, INC. | $73.03 | 2025 | Xiaflex, Aveed |
| Sumitomo Pharma America, INC. | $61.17 | 2024-2025 | Orgovyx |
| Axonics, INC. | $57.97 | 2022-2023 | Axonics |
| Merck Sharp & Dohme LLC | $56.45 | 2024-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Pfizer INC. | $45.90 | 2022-2025 | |
| 180 Medical, INC. | $43.96 | 2020-2023 | Gentlecath |
| Urogen Pharma, INC. | $43.66 | 2020-2025 | |
| Laborie Medical Technologies Corp. | $42.86 | 2024-2025 | Endosheath Technology, Optilume Bph Drug Coated Balloon Catheter |
| Allergan, INC. | $36.24 | 2021 | |
| Teleflex LLC | $35.02 | 2025 | Barrigel |
| Myriad Genetic Laboratories, INC. | $26.81 | 2021-2023 | Myrisk |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $18.77 | 2024 | Givlaari |
| Lilly USA, LLC | $18.25 | 2024 | Jaypirca, Retevmo, Verzenio |
| Tolmar Pharmaceuticals, INC. | $17.96 | 2019 | |
| Angiodynamics, INC. | $17.93 | 2024 | Nanoknife |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2023 | |
| Coloplast Corp | $14.00 | 2021 | |
| Ambu INC. | $8.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.